Issue with Evaluating Costs Over Time in a Context of Medical Guideline Changes: An Example in Myocardial Infarction Care Based on a Longitudinal Study from 1997 to 2018

References

• Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168(2):934–945. doi:10.1016/j.ijcard.2012.10.046
   PubMed Web of Science ®Google Scholar
• World Health Organisation. The top 10 causes of death 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed December 21, 2021.
   Google Scholar
• Public Health Agency of Canada. Report from the Canadian Chronic Disease Surveillance System: Heart Disease in Canada. Ottawa (Ontario): Public Health Agency of Canada; 2018. Report No.: 170308.
   Google Scholar
• Mendis S, Thygesen K, Kuulasmaa K, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol. 2011;40(1):139–146. doi:10.1093/ije/dyq165
   PubMed Web of Science ®Google Scholar
• Hunink MGM, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease, 1980–1990: the effect of secular trends in risk factors and treatment. JAMA. 1997;277(7):535–542. doi:10.1001/jama.1997.03540310033031
   PubMed Web of Science ®Google Scholar
• Tu JV, Nardi L, Fang J, et al. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004. CMAJ. 2009;180(13):E118–25. doi:10.1503/cmaj.081197
   PubMed Web of Science ®Google Scholar
• Canadian Cardiovascular Society. 1992 Canadian Consensus Conference on Coronary Thrombolysis; 1992.
   Google Scholar
• Canadian Cardiovascular Society. Indications for and Access to Revascularization; 1995.
   Google Scholar
• Armstrong PW, Bogaty P, Buller CE, Dorian P, O’Neill BJ. The 2004 ACC/AHA Guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. Can J Cardiol. 2004;20(11):1075–1079.
   PubMed Web of Science ®Google Scholar
• Welsh RC, Travers A, Huynh T, Cantor WJ. Canadian Cardiovascular Society Working Group: providing a perspective on the 2007 focused update of the American College of Cardiology and American Heart Association 2004 guidelines for the management of ST elevation myocardial infarction. Canadian J Cardiol. 2009;25(1):25–32. doi:10.1016/S0828-282X(09)70019-4
   PubMed Web of Science ®Google Scholar
• de Boer Sanneke PMS, Barnes EH, Westerhout CM. High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. Am Heart J. 2011;161(3):500–507. doi:10.1016/j.ahj.2010.11.022
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 4 ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• Trudel X, Gilbert-Ouimet M, Milot A, et al. Cohort Profile: the PROspective Quebec (PROQ) Study on Work and Health. Int J Epidemiol. 2018;47(3):693–693i. doi:10.1093/ije/dyy026
   PubMed Web of Science ®Google Scholar
• Régie de l’assurance maladie du Québec. Manuel des médecins omnipraticiens – rémunération à l’acte 2021. Available from: https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/manuels/syra/medecins-omnipraticiens/100-facturation-omnipraticiens/manuel-omnipraticiens-remuneration-acte.html. Accessed December 21, 2021.
   Google Scholar
• Régie de l’assurance maladie du Québec. Manuel des médecins spécialistes – rémunération à l’acte 2021. Available from: https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/manuels/syra/medecins-specialistes/150-facturation-specialistes/manuel-specialistes-remuneration-acte.html. Accessed December 21, 2021.
   Google Scholar
• Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54(6):1423–1428. doi:10.1161/HYPERTENSIONAHA.109.139279
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Ministère de la Santé et des Services sociaux. Cadre normatif du système MED-ÉCHO - Mise à jour 2021 2021. Available from: https://publications.msss.gouv.qc.ca/msss/document-000170/. Accessed December 21, 2021.
   Google Scholar
• Statistics Canada. Table 18- 10-0005-01Consumer Price Index, annual average, not seasonally adjusted 2020. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000501. Accessed December 21, 2021.
   Google Scholar
• CADTH. Guidance Document for the Costing of Health Care Resources in the Canadian Setting. 2nd ed. Ottawa: CADTH; 2016.
   Google Scholar
• Contandriopoulos D, Perroux M. Fee increases and target income hypothesis: data from Quebec on physicians’ compensation and service volumes. Healthc Policy. 2013;9(2):30–35.
   PubMedGoogle Scholar
• Hébert G. La rémunération des médecins québécois. IRIS; 2016.
   Google Scholar
• Tran DT, Ohinmaa A, Thanh NX, Welsh RC, Kaul P. The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada. Pharmacoecon Open. 2018;2(4):433–442. doi:10.1007/s41669-017-0061-0
   PubMed Web of Science ®Google Scholar
• Lambert L, Blais C, Hamel D, et al. Evaluation of Care and Surveillance of Cardiovascular Disease: can We Trust Medico-administrative Hospital Data? Canadian J Cardiol. 2012;28(2):162–168. doi:10.1016/j.cjca.2011.10.005
   PubMed Web of Science ®Google Scholar
• Robitaille C, Bancej C, Dai S, et al. Surveillance of ischemic heart disease should include physician billing claims: population-based evidence from administrative health data across seven Canadian provinces. BMC Cardiovasc Disord. 2013;13:88. doi:10.1186/1471-2261-13-88
   PubMed Web of Science ®Google Scholar
• Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004;57(2):131–141. doi:10.1016/S0895-4356(03)00246-4
   PubMed Web of Science ®Google Scholar
• Wong GC, Welsford M, Ainsworth C, et al. 2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: focused Update on Regionalization and Reperfusion. Can J Cardiol. 2019;35(2):107–132. doi:10.1016/j.cjca.2018.11.031
   PubMed Web of Science ®Google Scholar
• Roggeri A, Gnavi R, Dalmasso M, et al. Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis. Crit Pathw Cardiol. 2013;12(4):204–209. doi:10.1097/HPC.0b013e3182a78c06
   PubMedGoogle Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529–555. doi:10.1161/CIR.0b013e3182742c84
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation. 2004;110(9).
   Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Guertin JR, Mitchell D, Ali F, LeLorier J. Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug. Clinicoecon Outcomes Res. 2015;7:497–503. doi:10.2147/CEOR.S90386
   PubMedGoogle Scholar